Regents Of The University Of California Nurix Therapeutics, Inc. Transaction History

Regents Of The University Of California

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$7.88 - $14.82 $1.61 Million - $3.03 Million	-204,123 Closed	0 $0
Q4 2021 Jan 24, 2022	SELL	$26.43 - $34.5 $9.7 Million - $12.7 Million	-367,089 Reduced 64.26%	204,123 $5.91 Million
Q2 2021 Jul 27, 2021	BUY	$24.21 - $35.89 $13.8 Million - $20.5 Million	571,212 New	571,212 $15.2 Million

184

66.3M

40.9K

106K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.18B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.